DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Acyl-CoA-binding protein as a driver of pathological aging
The tissue hormone acyl coenzyme A–binding protein (ACBP, encoded by the gene diazepam-binding inhibitor, DBI) has been implicated in various facets of pathological aging. Here, we show that ACBP plasma concentrations are elevated in (close-to-)centenarians (mean ± SD age 99.5 ± 4.5 y) commensurate with their health deterioration, correlating with a reduced glomerular filtration rate and a surge in senescence-associated cytokines. ACBP neutralization by means of a monoclonal antibody (mAb) improved health span in a strain of progeroid mice. In a mouse model of chronic kidney injury induced by cisplatin, anti-ACBP mAb administration counteracted both histopathological and functional signs of organ failure. ACBP inhibition also prevented the senescence of tubular epithelial cells and glomerular podocytes induced by cisplatin or doxorubicin, respectively, as measurable by the immunohistochemical detection of cyclin-dependent kinase inhibitor 1A (CDKN1A, best known as p21). Senescence was also prevented by anti-ACBP mAb treatment in additional mouse models of accelerated aging. This applied to liver damage induced by a combination of high-fat diet and carbon tetrachloride, where hepatic cells become senescent. Moreover, administration of anti-ACBP mAb prevented natural and doxorubicin-accelerated cardiomyocyte senescence. We performed single-nucleus RNA sequencing to study the transcriptome of hearts that had been exposed to doxorubicin and/or anti-ACBP in vivo. In cardiomyocytes, doxorubicin caused an anti-ACBP-reversible dysregulation of mRNAs coding for cardioprotective proteins involved in autophagy, fatty acid oxidation, mitochondrial homeostasis, and oxidative phosphorylation. Altogether, these findings plead in favor of a broad age-promoting effect of ACBP across different organ systems., We also thank Agustín Brea Pastor from the University of Oviedo for his help with the computer tomographic imaging process. G.K. receives grants by the Ligue contre le Cancer (équipes labellisées); Institut National du Cancer (INCa); European Union Horizon 2020 research and innovation programmes Oncobiome (grant agreement number: 825410), Prevalung (Grant agreement number 101095604), Agence Nationale de la Recherche under the France 2030 programme (reference number 21-ESRE-0028, ESR/Equipex+ Onco-Pheno-Screen); INCa; Agence Nationale de la Recherche (ANR), i.e., French Ministry of Health PIA5, ANR, program RHU5 “ANR-21-RHUS-0017” IMMUNOLIFE and ANR-23-RHUS-0010 LUCA-pi; Seerave Foundation, an European Research Council Advanced Investigator Award (ERC-2021-ADG, Grant No. 101052444; project acronym: ICD-Cancer) and Site de reserche intégrée sur le cancer (SIRIC) Cancer Research and Personalized Medicine (CARPEM, SIRIC CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006 supported by INCa, Ministère des Solidarités et de la Santé and INSERM). This study contributes to the IdEx Université de Paris Cité ANR-18-IDEX-0001. L.M-N. is supported by the FPI program (PRE2021-100065) funded by MCIN/ AEI /10.13039/501100011033. C.B. is supported by the Ramon y Cajal program (RYC2021-031291-I) funded by MICIN/AEI/10.13039/50100011033 and cofunded by European Union NextGenerationEU/PRTR. C.R-L is supported by the Biomedical Research Networking Centre on Frailty and Healthy Aging (CIBERFES, CB16/10/00314). Research by C.F.L. is funded by Instituto de Salud Carlos III (ISCIII) and cofunded by the European Union through projects PI20/00645, PI23/00396, and FORT23/00023, and by the MCIN/AEI/10.13039/501100011033 and «Next Generation EU»/PRTR (project CNS2023-144144). We thank Rosalba Gestión (nursing homes of Sevilla La Nueva, Madrid, Spain). M.A. acknowledges support from the Medical University of Graz (Start Fund, Flagship Project VASC-HEALTH and the excellence cluster MetAGE), BioTechMed-Graz (Young Researcher Group), the Austrian Science Fund (FWF; DOI: https://doi.org/10.55776/P34926 & DOI: https://doi.org/10.55776/COE14), and the European Commission (H2020-MSCA-IF). M.A. and G.K. received funding from FWF (DOI: https://doi.org/10.55776/I6931) and ANR (Ener-LIGHT consortium) under the umbrella of the Partnership Fostering a European Research Area for Health (ERA4Health) (GA N° 101095426 of the EU Horizon Europe Research and Innovation Programme. O.M. is supported by the “Beatriz Galindo Junior” Program from the Spanish Ministry of Universities (BG22/00104). Research by A.L. and C.F.L. is funded by Wereld Kanker Onderzoek Fonds as part of the World Cancer Research Fund International grant program (IIG_FULL_2021_007)., Peer reviewed